tradingkey.logo
tradingkey.logo
Search

Bluejay Diagnostics Inc

BJDX
Add to Watchlist
0.877USD
-0.053-5.67%
Close 07-31 16:00ETQuotes delayed by 15 min
907.03KMarket Cap
LossP/E TTM

Bluejay Diagnostics Inc

0.877
-0.053-5.67%
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-5.67%

5 Days

-14.89%

1 Month

-26.95%

6 Months

-75.78%

Year to Date

-67.15%

1 Year

-41.56%

Key Figures
0.950Open
0.950High
111.64KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
10.79%Turnover Ratio
0.929Prev. Close
0.870Low
67.28KTurnover
LossP/E Static
0.22P/B
0.00%Div Yield TTM
-126.94%ROA
16.68052wk High
0.41Volume Ratio
-34.16MNet Profit
1.03MShares
-49.4930EPS TTM
0.81Beta
-171.56%ROE
1.62352wk Low
8.61%Amplitude
19.64%Gross Margin
907.03KMarket Cap
-2.72Reward/Risk
6.79%Risk Rate

Key Insights

Bluejay Diagnostics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 187 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Bluejay Diagnostics Inc's Score

Industry at a Glance

Industry Ranking
187 / 385
Overall Ranking
345 / 4281
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Bluejay Diagnostics Inc Highlights

StrengthsRisks
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
Fairly Valued
The company’s latest PE is -0.02, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 42.23K shares, increasing 23.42% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.41.

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space

Bluejay Diagnostics Inc News

More news coming soon, stay tuned...

Indicators

Indicators
Sell(3)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
0.065
Neutral
RSI(14)
31.763
Neutral
STOCH(KDJ)(9,3,3)
11.529
Oversold
ATR(14)
0.147
Low Volatility
CCI(14)
-116.476
Sell
Williams %R
95.890
Oversold
TRIX(12,20)
-3.795
Sell
StochRSI(14)
15.815
Sell
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
0.954
Sell
MA10
1.046
Sell
MA20
1.191
Sell
MA50
2.457
Sell
MA100
2.175
Sell
MA200
3.385
Sell

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Bluejay Diagnostics Inc Info

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
Ticker SymbolBJDX
CompanyBluejay Diagnostics Inc
CEODey (Neil)
Websitehttps://bluejaydx.com/

Shareholders

Shareholders
Shareholders
Proportion
Lichti (Braeden William Sinclair)
2.37%
Intracoastal Capital, L.L.C.
1.72%
Armistice Capital LLC
1.57%
Northstrive Fund II LP
1.06%
Citadel Advisors LLC
1.01%
Other
92.27%

FAQs

What is the current price of Bluejay Diagnostics Inc (BJDX)?

The current price of Bluejay Diagnostics Inc (BJDX) is 0.88.

What is the symbol of Bluejay Diagnostics Inc?

The ticker symbol of Bluejay Diagnostics Inc is BJDX.

What is the 52-week high of Bluejay Diagnostics Inc?

The 52-week high of Bluejay Diagnostics Inc is 16.68.

What is the 52-week low of Bluejay Diagnostics Inc?

The 52-week low of Bluejay Diagnostics Inc is 1.62.

What is the market capitalization of Bluejay Diagnostics Inc?

The market capitalization of Bluejay Diagnostics Inc is 907.03K.

What is the Earnings Per Share (EPS TTM) of Bluejay Diagnostics Inc (BJDX)?

The Earnings Per Share (EPS TTM) of Bluejay Diagnostics Inc (BJDX) is -61.01.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.